Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00814073 · ClinicalTrials.gov registry record · Phase 3
Masitinib in Severe Indolent or Smoldering Systemic Mastocytosis
A Phase 3 study of Indolent Systemic Mastocytosis, sponsored by AB Science.
- Completed
- Registry status
- Phase 3
- Development phase
- 135
- Enrollment target
- 20
- Study locations
NCT00814073 is a Phase 3 study of Indolent Systemic Mastocytosis that has completed, run by AB Science. The registered enrollment target is 135 participants, below the 302-participant average among 3 other Indolent Systemic Mastocytosis trials with a reported enrollment target (55% lower). The trial reports 20 study locations across 3 states.
The verdict
NCT00814073, a Phase 3 study of Indolent Systemic Mastocytosis, has completed, sponsored by AB Science.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 135 participants
- Enrollment target
- 20
- Study locations
Study Summary
The objective of this study is to compare the safety and efficacy of masitinib (AB1010) to placebo in patients with mastocytosis with handicap.
Conditions Studied
Interventions
- DRUG Placebo
- OTHER Best Supportive Care
- DRUG Masitinib
Study Locations (20)
Other
- CHU d'Amiens - Amiens
- Hôpital Avicenne - Bobigny
- CHU de Brest - Brest
- CHU de Caen - Caen
- CHU Clermont Ferrand - Clermont-Ferrand
- Hôpital Claude Huriez - Lille
- CHU Dupuytren - Limoges
- Hôpital Ambroise Paré - Marseille
- Hôpital Nord - Marseille
- Hôpital Central - Nancy
- CHU Hôtel Dieu - Nantes
- Hôpital l'Archet II - Nice
- Hôpital Necker - Paris
- Hôpital Tenon - Paris
- CHU Lyon Sud - Pierre-Bénite
- Centre Hospitalier Lyon Sud - Pierre-Bénite
- CHU Milétrie - Poitiers
- CHU Hôpital Sud - Rennes
California
- UC Davis Health System , Department of Dermatology - Sacramento
Texas
- MD Anderson Cancer Centre - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 135 participants |
| Start Date | 2008-12 |
| Est. Completion | 2015-11 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00814073
The ClinicalTrials.gov registry entry for NCT00814073 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 135 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 302-participant average among 3 other Indolent Systemic Mastocytosis trials with a reported enrollment target (55% lower). The listed sponsor is AB Science, which has 8 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Indolent Systemic Mastocytosis appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.
NCT00814073 reports 20 study locations spanning 3 distinct geographic areas - top geographies include Other, California, Texas.
Frequently Asked Questions
What is clinical trial NCT00814073 about?
NCT00814073 is a clinical study titled "Masitinib in Severe Indolent or Smoldering Systemic Mastocytosis". The objective of this study is to compare the safety and efficacy of masitinib (AB1010) to placebo in patients with mastocytosis with handicap.
What is the current status of trial NCT00814073?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 135 participants. The study started on 2008-12. Estimated completion is 2015-11.
What conditions does trial NCT00814073 study?
This clinical trial studies the following conditions: Indolent Systemic Mastocytosis.
What interventions are being tested in trial NCT00814073?
The interventions under investigation include: Placebo (DRUG), Best Supportive Care (OTHER), Masitinib (DRUG).
Who is sponsoring clinical trial NCT00814073?
This trial is sponsored by AB Science, which has 8 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00814073 being conducted?
This trial has 20 study locations across California, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Indolent Systemic Mastocytosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study of TL-895 in Subjects With Myelofibrosis or Indolent Systemic Mastocytosis
RECRUITING · Phase 2
-
(HARBOR) Study to Evaluate Efficacy and Safety of BLU-263 Versus Placebo in Patients With Indolent Systemic Mastocytosis
RECRUITING · Phase 2
-
(PIONEER) Study to Evaluate Efficacy and Safety of Avapritinib (BLU-285), A Selective KIT Mutation-targeted Tyrosine Kinase Inhibitor, Versus Placebo in Patients With Indolent Systemic Mastocytosis
ACTIVE NOT RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.